XÂY DỰNG MÔ HÌNH PHÂN TÍCH CHI PHÍ – HIỆU QUẢ EMICIZUMAB TRONG DỰ PHÒNG SO VỚI CHẤT BẮC CẦU TRONG ĐIỀU TRỊ THEO NHU CẦU TRÊN NGƯỜI BỆNH HEMOPHILIA A

Abstract

Prophylaxis treatment of bleeding in patients with hemophilia A (HA) helps limit bleeding, prevent and minimize complications. Emicizumab is a prophylactic drug for HA, used in the European Union, the US, Japan and many countries around the world [10] with proven effectiveness and safety by many clinical studies [5]. However, the high cost of the drug is a huge barrier against wider application. Thus, it is necessary to evaluate the feasibility of drug using in clinical practice based  on a cost-effectiveness analysis, in which the first important step is to build  up a specific model for Vietnamese patient population. The model allows cost-effectiveness analysis of emicizumab prophylaxis compared with on-demand bypass agent therapy in the treatment of hemophilia A bleeding in Vietnam. Using modelling methods combined with literature review and consultation with clinical experts, the study builds a cost-effectiveness analysis model based on Microsoft Excel 2016 with a model structure factoring in the particular clinical settings of Vietnam.